BreathDraw: a breath analyzer for early disease detection and precision medicine
Lead Participant:
BIOXHALE LTD
Abstract
"Continue to implement the NHS Long Term Plan, focusing on transformation of services, to support NHS resilience, and continue to inspire public confidence" The Government's 2021-22 mandate to NHS England.
Our game-changing breath testing technology will help transform healthcare services support our NHS by reducing costs (£1B), appointments/referrals, ineffective treatments, and repeated emergency admissions.
Our non-invasive and innovative breath sampler can offer early-stage disease diagnosis, providing the right patient the right treatment at the right time, thus improving patient treatment outcome and quality-of-life.
Every time we breathe out, we exhale hundreds of chemicals that reflect our biochemistry and lung conditions such as asthma and other diseases. Our medium-term target (Year 4) is respiratory disease with better management of asthma. Breath-analysis can revolutionize the healthcare of the world's 339M asthmatics by targeting precision medicine. In the UK, the current "trial and error" approach to asthmatics treatment results in \>70,000 hospital admissions pa, with 200,000 bed-days and \>1,400 deaths pa. Asthma treatment costs the NHS £1.1B pa; asthma costs wider-society much more, £10B pa accompanied by suffering and reduced quality-of-lives lived.
Society needs new emerging technologies for early-stage non-invasive patient diagnosis, for this will save on treatment costs and reduce suffering and wider economic impacts. Our proposition is to deliver a non-invasive, easy-to-use, high-performance, fast, environmentally friendly and affordable breath sampling device to guide diagnostics, precision medicine, reduce care-costs and improve patients' quality-of-life. We think costly "trial and error" approaches with avoidable hospital admissions should be consigned to history.
The business potential is significant. The global breath analyser market is estimated as $933M in 2021, growing at a CAGR of 7.88%. Future opportunities for growth include early-stage diagnosis for COPD (available market £6.5B 2021), cancer (£144B 2018), and CBRN-exposure detection (£1B 2021).
It is time for Bioxhale to deliver benefits to patients, their carers and loved ones, healthcare services and wider society. The project is timely, and with our disruptive product we can strongly position ourselves in the breath analyser market. The wider outcome of this project will have a significant social, economic, and environmental impact in the UK and across the world.
Our game-changing breath testing technology will help transform healthcare services support our NHS by reducing costs (£1B), appointments/referrals, ineffective treatments, and repeated emergency admissions.
Our non-invasive and innovative breath sampler can offer early-stage disease diagnosis, providing the right patient the right treatment at the right time, thus improving patient treatment outcome and quality-of-life.
Every time we breathe out, we exhale hundreds of chemicals that reflect our biochemistry and lung conditions such as asthma and other diseases. Our medium-term target (Year 4) is respiratory disease with better management of asthma. Breath-analysis can revolutionize the healthcare of the world's 339M asthmatics by targeting precision medicine. In the UK, the current "trial and error" approach to asthmatics treatment results in \>70,000 hospital admissions pa, with 200,000 bed-days and \>1,400 deaths pa. Asthma treatment costs the NHS £1.1B pa; asthma costs wider-society much more, £10B pa accompanied by suffering and reduced quality-of-lives lived.
Society needs new emerging technologies for early-stage non-invasive patient diagnosis, for this will save on treatment costs and reduce suffering and wider economic impacts. Our proposition is to deliver a non-invasive, easy-to-use, high-performance, fast, environmentally friendly and affordable breath sampling device to guide diagnostics, precision medicine, reduce care-costs and improve patients' quality-of-life. We think costly "trial and error" approaches with avoidable hospital admissions should be consigned to history.
The business potential is significant. The global breath analyser market is estimated as $933M in 2021, growing at a CAGR of 7.88%. Future opportunities for growth include early-stage diagnosis for COPD (available market £6.5B 2021), cancer (£144B 2018), and CBRN-exposure detection (£1B 2021).
It is time for Bioxhale to deliver benefits to patients, their carers and loved ones, healthcare services and wider society. The project is timely, and with our disruptive product we can strongly position ourselves in the breath analyser market. The wider outcome of this project will have a significant social, economic, and environmental impact in the UK and across the world.
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| BIOXHALE LTD | £47,586 | £ 47,586 |
People |
ORCID iD |
| Dahlia Salman (Project Manager) |